Articles tagged with Biomarkers
A novel approach to analyzing human blood plasma's low-abundant N-glycoproteome has been developed, enabling the reliable identification of rare and modified glycans. This workflow can detect glycoproteins with concentrations as low as 6.31 pg·mL−1, expanding the range by five orders of magnitude.
Researchers at TUM developed an AI-powered algorithm to predict kidney damage in prostate cancer patients undergoing lutetium-177 PSMA therapy. Early detection could enable personalized treatment adjustments to prevent organ damage.
Researchers at Karolinska Institutet have identified new biomarkers in urine that can indicate the presence and severity of prostate cancer with high precision. The findings surpass current blood biomarker PSA in terms of diagnostic accuracy.
New molecular testing methods are transforming post-transplant care by detecting potential heart injury or rejection earlier than traditional biopsies. This enables physicians to reduce immunosuppressive medicine dosage in low-risk patients, potentially improving patient outcomes beyond the first year post-heart transplant.
A misfolded protein in spinal fluid facilitates reliable Parkinson's diagnosis even in its early stages. The biomarker has a sensitivity and specificity of over 90%, making it a promising tool for disease management and potential therapy development.
Researchers identified five blood proteins that can predict liver disease up to 16 years before symptoms. The combined levels of these proteins achieved high accuracy in predicting disease onset and progression, suggesting potential for early diagnosis and treatment.
Researchers used AI-driven methods to analyze thousands of digital images of melanoma tumor tissue, identifying key immune cell structures that boost immunotherapy effects. The presence of these structures was linked to significantly better overall survival for patients with advanced melanoma.
The study found that serum-derived hsa_circ_101555 showed excellent diagnostic accuracy in differentiating HCC patients from healthy controls. It also demonstrated a prognostic role in predicting tumor progression and response to therapy, with significant correlations with markers of liver inflammation and tumor features.
A study on captive olive baboons found that about a quarter exhibited accelerated aging, while another quarter showed signs of slower aging. The researchers investigated physical indicators such as walking speed and fine motor skills, but found that these changes were more closely related to chronological age than epigenetic age.
A new version of Caltech's smart bandage, iCares, has been shown to continually sample fluid from human patients with chronic wounds, providing real-time data on biomarkers present. The bandage can detect molecules such as nitric oxide and hydrogen peroxide, potentially up to three days before symptoms appear.
A team of Singaporean scientists has released a comprehensive long-read RNA sequencing dataset, SG-NEx, to accelerate biomarker discovery and precision medicine. The dataset offers deeper biological insights into RNA complexity, enabling researchers to detect clinically relevant biomarkers and develop better treatments.
A new study reveals promising progress toward predicting how patients with major depressive disorder will respond to antidepressant medications. Brain connectivity patterns were found to significantly improve predictions of treatment response across two large, independent clinical trials.
Liquid biopsy analyzes circulating tumor components in body fluids to detect cancer at early stages, offering a safer and more dynamic alternative to traditional tissue biopsies. This non-invasive approach has shown promise in detecting various types of cancer, including lung, breast, colorectal, prostate, and gastric cancers.
A new analysis found that oral hormone therapy can lower levels of lipoprotein(a), a genetic risk factor associated with higher risk of heart attack and stroke. Hormone therapy also improved biomarkers of cardiovascular health, including cholesterol levels.
A new study from Columbia University Mailman School of Public Health found significant associations between cognition and established risk factors for Alzheimer's disease in individuals aged 24-44. The researchers used biomarkers related to cognitive impairment and cardiovascular health to predict long-term trajectories of cognitive de...
Researchers developed a blood test analyzing messenger RNA to detect cancers, track treatment resistance, and monitor tissue injury. The test increased cancer detection by over a factor of 50 and provides useful information for non-cancer applications, such as COVID-19 severity and lung health.
Participants who took the supplement showed improvements in grip strength, lower body mobility, and reductions in body weight. The supplement appeared to reduce stem cell turnover, regulate immune function, and influence gene activity related to stress response.
A study has identified an early blood marker for hereditary Alzheimer's disease, beta-synuclein, which can detect neurodegeneration up to 11 years before dementia symptoms. This biomarker could help with early diagnosis and treatment, improving the potential of new medicines for Alzheimer's.
Researchers developed a new method to measure changes in DNA that can help predict a person's age, focusing on how random chemical tags become over time. The study found that methylation entropy predicted age as accurately as traditional methods, with an average error of just five years.
Researchers evaluated different types of Glasgow Outcome Scale Extended (GOSE) scores among US trauma center patients. They found that GOSE-All scores capture the combined effect of brain and extracranial injuries, while GOSE-TBI scores exclude extracranial injury effects.
Dr Ambrish Mithal, an Indian endocrinologist, has been awarded the prestigious IOF CSA Medal of Achievement for his groundbreaking work in advancing the field of osteoporosis. His pioneering efforts have significantly increased understanding and awareness of osteoporosis globally.
A pioneering study has identified interleukin-6 (IL-6) as a powerful diagnostic biomarker for the early detection of sepsis in high-risk patient groups. IL-6 outperformed traditional biomarkers in distinguishing bacterial from non-bacterial infections and stratifying sepsis severity.
Researchers found that cortisol levels were lower in survivors, while heart rate and blood pressure responses were altered. Interleukin 1B was significantly higher, suggesting potential long-term health problems despite healthy symptoms.
Researchers at The University of Texas at San Antonio are working on a new AI tool to improve lives after brain injury. They plan to analyze data from 3,000 veterans and develop an interactive dashboard for clinicians to use, providing insights that could revolutionize treatment.
A new analytical method has been developed to measure plasma P-tau217, a blood-based marker that can change several years before Alzheimer's symptoms appear. The fully automated method demonstrated high accuracy of over 90% in various settings, including primary care and specialized memory clinics.
Researchers have validated a blood test for early detection of Alzheimer's disease, achieving over 90% accuracy in hospital patients. The test uses a biomarker called phospho-tau217 and has the potential to reduce costs associated with current diagnostic tests, improving access to care and treatment.
A new system for early detection of Autism Spectrum Disorder (ASD) has been developed using virtual reality and artificial intelligence. The system, which uses biomarkers related to behavior, motor activity, and gaze direction, achieves an accuracy of over 85%, surpassing traditional methods.
A new study published in Nature Medicine has investigated the potential of specific biomarkers to predict dementia risk up to ten years before diagnosis. The study found that low levels of certain biomarkers may rule out future dementia, but elevated levels alone are not reliable for identification.
A recent study published in the Journal of Ageing and Physical Activity found that older adults exhibit similar or even less muscle damage than young adults after exercise. Muscle soreness was consistently lower in older adults, with reductions of around 34% at 48 hours and 62% at 72 hours compared to younger individuals.
The UK's first water monitoring center is launched to detect disease outbreaks and community health issues. Researchers will analyze wastewater samples from four urban areas, tracking chemicals and biological markers to identify early warning signs of infectious diseases and chronic health conditions.
Cognitive neuroscientists are using VR to develop innovative ways to assess cognitive decline, particularly in identifying age-related differences in spatial memory navigation. The study found significant impacts on memory performance due to the build-up of Alzheimer's proteins in the brain.
A study published in GeroScience found that weight training improves memory and brain anatomy in older adults with mild cognitive impairment. The results showed that strength training protected against atrophy in key brain areas associated with Alzheimer's disease.
A new consensus paper emphasizes the role of bone turnover markers (BTMs) in diagnosing and managing osteoporosis. BTMs, such as procollagen type I N propeptide (PINP) and β-isomerized C-terminal telopeptide of type I collagen (β-CTX-I), are invaluable tools for predicting fracture risk and monitoring treatment adherence.
Researchers developed a blood test that accurately diagnoses Alzheimer's disease and measures its progression. The test correlates with the amount of tau aggregates in the brain, distinguishing between early- and late-stage diseases.
The Association for Molecular Pathology (AMP) has won a court ruling that vacates the FDA's rule on laboratory-developed test procedure regulation. This decision will avoid adding billions of dollars in healthcare costs and protect access to high-quality care for hundreds of millions of Americans.
Researchers have identified six promising biomarkers that can detect drug-induced kidney injury earlier than traditional markers, enabling more timely monitoring during drug development. These biomarkers could lead to the development of safer medications and improve patient outcomes.
Researchers propose GLDH as a more liver-specific biomarker for detecting liver injury, offering greater specificity than current ALT and AST tests. The test performed similarly to ALT for detecting liver injury but was not impacted by associated muscle injury.
A novel PET imaging approach has effectively quantified the COX-2 enzyme in human brains, opening doors for its use in clinical settings for various brain disorders. This breakthrough could lead to earlier disease detection and monitor disease progression with anti-inflammatory treatments.
A study using NHANES data found that inflammation, rather than diet and exercise, has the strongest association with telomere shortening. Managing chronic inflammation may be key to preserving telomere length and promoting healthy aging.
A team of scientists has created a new method to selectively modify specific proteins in complex biological environments. They achieved this using aptamers and deoxyoxanosine, allowing precise conjugation of desired sites on target proteins. This breakthrough technology has the potential to revolutionize cancer diagnosis and treatment.
A study confirms plasma p-tau217 as a blood-based biomarker for early Alzheimer's detection in Asian populations. Higher levels correlate with faster cognitive decline, suggesting its potential role as both diagnostic and predictor tool.
A simple urine test has shown promising results in detecting early-stage kidney cancer recurrence, with a high sensitivity and specificity rate. The GAGome test can accurately identify patients at risk of recurrence, potentially reducing the need for invasive scans and enabling faster treatment access.
Dr. Amit Bar-Or is awarded the 2025 John Dystel Prize for his contributions to neuroimmunology and precision medicine in multiple sclerosis research. His work has led to significant advancements in disease mechanisms, treatment approaches, and biomarker studies.
CHEST MedCast offers over 400 videos and podcasts with personalized content recommendations, available on-demand and at any time from any device. The platform features an algorithm-based recommendation engine and up to 100 available CME credits/MOC points.
Researchers found that suppressing ZNF638 triggers an antiviral immune response in glioblastoma patients, making them more susceptible to treatment. This finding offers a potential new treatment strategy for the disease, which has remained challenging despite recent advances in immunotherapy.
A USC study found proteins and pathways involved in inflammation are associated with changes in bone mineral density (BMD) over time. The research identified potential biomarkers that could serve as early indicators of a person's risk for bone health issues later in life.
Researchers at the University of Texas at El Paso have developed a portable, blood-based device that can detect colon cancer using a biomarker called CCSP-2. The device has the potential to provide early detection and treatment options for this second-deadliest US cancer, making it a significant advancement in colorectal cancer screening.
Recent research suggests that some invasive cancers diagnosed in early-stage breast cancer may not need immediate surgery, highlighting the importance of more precise screening methods for DCIS. The COMET trial found that at least half of invasive breast cancers take years to progress or may never progress at all.
Researchers at MD Anderson have made significant breakthroughs in understanding pancreatic cancer's evolutionary process and developing new treatment strategies. They also discovered that surgical resection can enhance antitumor response in patients receiving immune checkpoint therapy for advanced kidney cancer.
Promoting cardiovascular health may help alleviate neurodegenerative disease burden in older adults, particularly among Black adults. The study found a positive correlation between cardiovascular health and biomarkers of neurodegenerative disease.
Researchers have discovered a blood test that can identify patients with a sleep disorder who are most likely to develop Dementia with Lewy Bodies. The blood test analyzes two proteins in the blood associated with Alzheimer's disease and predicted dementia risk in almost 90% of patients, four years before symptoms appeared.
Researchers at Kyushu University have discovered a way to predict a potentially life-threatening side effect of cancer immunotherapy before it occurs. By analyzing cerebrospinal fluid, they identified specific proteins associated with an immune response that can affect the central nervous system after therapy.
Research finds that certain viral antibodies and genetic risk factors can increase MS risk, with elevated antibody levels combined with a specific gene variant associated with strong increased risk. The study also identifies potential biomarkers for early diagnosis.
Researchers found that p-tau proteins in blood are elevated in both Alzheimer's and ALS patients, making them less specific for Alzheimer's diagnosis. However, they also show promise as potential biomarkers for early detection of ALS or monitoring disease progression.
A study by Flinders University found that certain bacteria in the throat may indicate greater health vulnerability in older adults. The presence of Staphylococcus aureus was linked to higher mortality rates, even after adjusting for other health factors.
Researchers at MD Anderson Cancer Center have identified biomarkers for predicting treatment response in metastatic breast cancer and found a potential target for tumor progression in pancreatic cancer. Additionally, they discovered that abnormal chromosome changes predict survival in patients with secondary acute myeloid leukemia.
Researchers analyzed pre-treatment CT scans of patients with head and neck squamous cell carcinoma to identify radiomic biomarkers that can predict the aggressiveness of the disease and its response to treatment. These biomarkers may lead to more targeted therapies and improved survival outcomes for patients.
Researchers introduce a dual threshold classifier to interpret circulating tumor DNA levels, enabling earlier detection of disease progression and personalized treatment. The study confirms that ctDNA levels are superior to traditional biomarkers like CA15-3.
Only about 1 in 5 older Americans have undergone cognitive screening in the past year, highlighting a persistent barrier to diagnosis and treatment. Researchers emphasize the importance of early conversations about cognitive health to prevent progression and improve outcomes.
A panel of experts identified key biomarkers for PND through a comprehensive literature review of 194 clinical studies. The study highlights the potential for these biomarkers to predict and diagnose PND, improving postoperative cognitive health in elderly patients.